Ose Immunotherapeutics SA - ESG Rating & Company Profile powered by AI
The Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Climate Action' and 'Peace, Justice & Strong Institutions'. The assessment of Ose Immunotherapeutics SA was prepared by All Street Sevva using advanced artificial intelligence. Alternative corporations in the scoring industry group for Ose Immunotherapeutics SA are displayed.
Ose Immunotherapeutics SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Ose Immunotherapeutics SA | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ose Immunotherapeutics SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Ose Immunotherapeutics SA report the average age of the workforce?
Sign up for free to unlockDoes Ose Immunotherapeutics SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose cybersecurity risks?
Sign up for free to unlockDoes Ose Immunotherapeutics SA offer flexible work?
Sign up for free to unlockDoes Ose Immunotherapeutics SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ose Immunotherapeutics SA conduct supply chain audits?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ose Immunotherapeutics SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose water use targets?
Sign up for free to unlockDoes Ose Immunotherapeutics SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Ose Immunotherapeutics SA have a product recall in the last two years?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose incidents of discrimination?
Sign up for free to unlockDoes Ose Immunotherapeutics SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ose Immunotherapeutics SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose parental leave metrics?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ose Immunotherapeutics SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ose Immunotherapeutics SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ose Immunotherapeutics SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose its waste policy?
Sign up for free to unlockDoes Ose Immunotherapeutics SA report according to TCFD requirements?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose energy use targets?
Sign up for free to unlockDoes Ose Immunotherapeutics SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ose Immunotherapeutics SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ose Immunotherapeutics SA
These potential risks are based on the size, segment and geographies of the company.
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.